Zarate Jean Mary, Boksa Patricia, Baptista Trino, Joober Ridha
Department of Neurology and Neurosurgery, McGill University and Douglas Hospital Research Centre, H4H 1R3, Montréal, Québec, Canada.
Psychopharmacology (Berl). 2004 Jan;171(2):162-72. doi: 10.1007/s00213-003-1553-4. Epub 2003 Nov 13.
Schizophrenia is a heterogeneous syndrome both at the etiological and clinical levels. In particular, patients with schizophrenia exhibit important variability in their therapeutic and metabolic responses to clozapine, an antipsychotic medication.
Here, we determine whether two mouse strains show differing clozapine responses with respect to weight gain, enhancement of prepulse inhibition of acoustic startle, and reversal of amphetamine-induced locomotion. Observed between-strain differences may be partly due to genetic factors that can be subsequently mapped using quantitative genetic approaches.
We treated the A/J and C57BL/6J inbred mouse strains with clozapine for 22 days. Prepulse inhibition and amphetamine-induced locomotion were measured after 3-4 days of clozapine treatment and again after 21-22 days of treatment. Weight gain was also monitored during treatment. RESULTS. Three-day treatment with clozapine increased prepulse inhibition in both strains. Four-day clozapine treatment reduced amphetamine-induced locomotion only in the C57BL/6J strain. Long-term (21-22 days) clozapine treatment did not affect these behaviors in either strain. After an initial weight loss during the first 5 days, clozapine (4 mg/kg) induced a significant weight gain in both strains.
The reversal of schizophrenia-related behaviors after short-term, but not long-term, clozapine treatment is consistent with other rodent studies. Although short-term clozapine treatment reduced amphetamine-induced locomotion only in the C57BL/6J strain, strain differences in amphetamine responses confound the interpretation of these results; therefore, quantitative genetic approaches may be difficult to carry out with this trait. In contrast, enhancement of prepulse inhibition after three days of clozapine treatment and weight gain induced by clozapine are relatively straightforward to quantify, making these trait more amenable to quantitative genetic approaches.
精神分裂症在病因和临床层面都是一种异质性综合征。特别是,精神分裂症患者在对氯氮平(一种抗精神病药物)的治疗和代谢反应方面表现出重要的变异性。
在此,我们确定两种小鼠品系在体重增加、惊吓前脉冲抑制增强以及安非他明诱导的运动行为逆转方面是否对氯氮平有不同反应。观察到的品系间差异可能部分归因于遗传因素,随后可使用数量遗传学方法进行定位。
我们用氯氮平处理近交系A/J和C57BL/6J小鼠品系22天。在氯氮平治疗3 - 4天后以及治疗21 - 22天后测量惊吓前脉冲抑制和安非他明诱导的运动行为。治疗期间也监测体重增加情况。结果:氯氮平治疗三天增加了两个品系的惊吓前脉冲抑制。氯氮平治疗四天仅在C57BL/6J品系中减少了安非他明诱导的运动行为。长期(21 - 22天)氯氮平治疗对两个品系的这些行为均无影响。在最初5天体重减轻后,氯氮平(4毫克/千克)在两个品系中均诱导出显著的体重增加。
短期而非长期氯氮平治疗后精神分裂症相关行为的逆转与其他啮齿动物研究一致。虽然短期氯氮平治疗仅在C57BL/6J品系中减少了安非他明诱导的运动行为,但安非他明反应的品系差异混淆了这些结果的解释;因此,用该性状进行数量遗传学方法可能很困难。相比之下,氯氮平治疗三天后惊吓前脉冲抑制的增强以及氯氮平诱导的体重增加相对容易量化,使这些性状更适合数量遗传学方法。